For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Genpact Ltd. (G) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Gem · Gem Score +46 (−100…+100 Quality+Value blend) · Quality 64 · Value 31 · Sentiment 16 (timing only, not weighted) · Composite fair value $58.45 vs $36.45 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Genpact Ltd.
G NYSEGenpact Ltd. is a global professional services and technology company specializing in digitally enabled business process management and transformation. The company designs, runs, and optimizes operations for enterprises across sectors such as banking and financial services, insurance, capital markets, consumer packaged goods, life sciences, healthcare, manufacturing, and high tech. Genpact’s offerings span digital operations, finance and accounting services, sourcing and procurement, risk and compliance, supply chain, customer service, and human resources. It also provides technology services including application development and management, cloud and data engineering, analytics, and artificial intelligence solutions tailored to industry-specific needs. By combining domain expertise with data-driven insights and automation, Genpact helps organizations streamline workflows, improve decision-making, and modernize legacy processes. The firm serves clients globally and generates a significant portion of its revenue from India. Founded in 1997 and headquartered in Hamilton, Bermuda, Genpact plays a notable role in the information technology services and business process outsourcing market.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.13
Total Equity: $2.55B
Shares: 176,646,644
Total Debt: $1.54B
Cash: $853.84M
EBITDA: $820.87M
Total Debt: $1.54B
Cash: $853.84M
Revenue: $5.08B
Revenue: $5.08B
Revenue: $5.08B
Total Equity: $2.55B
Tax Rate: 24.3%
Equity: $2.55B
Total Debt: $1.54B
Cash: $853.84M
Current Liabilities: $1.60B
Long-Term Debt: $1.17B
Total Debt: $1.54B
Total Equity: $2.55B
Shares: 176,646,644
Shares: 176,646,644
CapEx: -$78.20M
Shares: 176,646,644
Stock Price: $34.65
Net Income: $552.49M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 19, 2026 2:33pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.4B | $4.5B | $4.8B | $5.1B |
| Cost of Revenue | $2.6B | $2.8B | $2.9B | $3.1B | $3.2B |
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.7B | $1.8B |
| Operating Expenses | $923.0M | $1.0B | $939.8M | $988.0M | $1.1B |
| Operating Income | $509.0M | $502.2M | $630.9M | $702.1M | $750.2M |
| Net Income | $369.4M | $353.4M | $631.3M | $513.7M | $552.5M |
| EBITDA | $618.1M | $589.0M | $703.4M | $771.8M | $820.9M |
| EPS | $1.97 | $1.92 | $3.46 | $2.88 | $3.18 |
| EPS (Diluted) | $1.91 | $1.88 | $3.41 | $2.85 | $3.13 |
Balance Sheet (Annual)
Last updated: Aug 19, 2026 12:27pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $899.5M | $646.8M | $583.7M | $648.2M | $853.8M |
| Total Current Assets | $1.9B | $1.8B | $1.9B | $2.1B | $2.7B |
| Total Assets | $5.0B | $4.6B | $4.8B | $5.0B | $5.8B |
| Current Liabilities | $1.3B | $1.1B | $1.3B | $963.7M | $1.6B |
| Long-Term Debt | $1.3B | $1.2B | $824.7M | $1.2B | $1.2B |
| Total Liabilities | $3.1B | $2.8B | $2.6B | $2.6B | $3.3B |
| Total Equity | $1.9B | $1.8B | $2.2B | $2.4B | $2.5B |
| Retained Earnings | $732.5M | $780.0M | $1.1B | $1.2B | $1.4B |
Cash Flow (Annual)
Last updated: Aug 19, 2026 2:33pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $694.3M | $443.7M | $490.8M | $615.4M | $812.9M |
| Capital Expenditure | -$53.3M | -$50.6M | -$55.4M | -$82.8M | -$78.2M |
| Free Cash Flow | $640.9M | $393.1M | $435.4M | $532.7M | $734.7M |
| Acquisitions (net) | -$72.0M | $-33,000 | $-682,000 | $0 | -$80.4M |
| Net Debt Issued / (Repaid) | $316.0M | -$381.0M | -$19.9M | -$33.1M | $323.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$298.2M | -$214.1M | -$225.5M | -$252.7M | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 19, 2026 2:33pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +8.7% | +2.4% | +6.5% | +6.6% |
| Gross Profit Growth | +7.3% | +2.2% | +7.6% | +8.3% |
| Operating Income Growth | -1.3% | +25.6% | +11.3% | +6.9% |
| Net Income Growth | -4.3% | +78.6% | -18.6% | +7.6% |
| EBITDA Growth | -4.7% | +19.4% | +9.7% | +6.4% |
Dividend History (Last 20)
Last updated: Aug 19, 2026 1:56pm (4d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-10 | $0.19 | — | — | — |
| 2026-03-16 | $0.19 | — | — | — |
| 2025-09-11 | $0.17 | — | — | — |
| 2025-06-18 | $0.17 | — | — | — |
| 2025-03-11 | $0.17 | — | — | — |
| 2024-12-09 | $0.15 | — | — | — |
| 2024-09-11 | $0.15 | — | — | — |
| 2024-06-10 | $0.15 | — | — | — |
| 2024-03-08 | $0.15 | — | — | — |
| 2023-12-07 | $0.14 | — | — | — |
| 2023-09-07 | $0.14 | — | — | — |
| 2023-06-08 | $0.14 | — | — | — |
| 2023-03-09 | $0.14 | — | — | — |
| 2022-12-08 | $0.13 | — | — | — |
| 2022-09-08 | $0.13 | — | — | — |
| 2022-06-09 | $0.13 | — | — | — |
| 2022-03-09 | $0.13 | — | — | — |
| 2021-12-09 | $0.11 | — | — | — |
| 2021-09-09 | $0.11 | — | — | — |
| 2021-06-10 | $0.11 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 16:11| Case | Growth | Margin | Fair value | vs price ($36.45) |
|---|---|---|---|---|
| Bull — recovery | +10% | 13.8% | $68.52 | +88% |
| Base — stabilizes | +7% | 12.0% | $54.03 | +48% |
| Bear — keeps slipping | +3% | 10.2% | $41.76 | +15% |
| Stress — last quarter repeats | +6% | 10.8% | $47.30 | +30% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-12Genpact already owns the process, the SLAs, the exception paths and the change-management relationship inside ~thousands of enterprise workflows — the least glamorous, hardest-to-acquire part of deploying agents at an enterprise. If it re-prices to outcomes/transactions, it can deliver the same work with a fraction of the 125k-plus delivery base and keep the spread for a few renewal cycles.
The monetized unit is effectively FTE-linked. Every productivity gain becomes a client-visible savings claim at rebid, so AI shows up first as price-per-transaction deflation rather than margin. That is exactly the mechanism behind 2-3% organic growth and the -3.9% share gap versus a 10.5%-growing industry.
Whether Genpact converts a majority of revenue to outcome/transaction/consumption pricing BEFORE clients force productivity share-back on FTE contracts. Observable: disclosed share of non-FTE-priced bookings, revenue-per-employee trend, and headcount falling while revenue grows.
Regulated, liability-bearing operations run under contract — KYC/AML, claims adjudication, statutory close, pharmacovigilance — plus decades of client-specific exception logic and audit trails no enterprise wants to re-own. Enterprise procurement trust and multi-year embedded contracts are slower to copy than the software.
AI Lens thesis
Genpact's job — run someone else's back office better and cheaper than they can — survives cheap intelligence completely; its delivery model does not. Labor arbitrage was the scarce asset, and AI makes the arbitraged input abundant, so the price of a processed invoice, claim, or ticket falls toward the cost of inference. Genpact's defense is that it holds the messy last mile: exception handling, regulatory accountability, integration into a client's specific ERP mess, and a client base that genuinely does not want to own compliance operations. That shield is real but thinner than PAYC's, because Genpact is not a system of record — SAP, Oracle, Workday and ServiceNow can embed agents directly in the system where the transaction lives and route around the BPO layer, and AI-native service startups can bid per-outcome with no labor base to defend. Structurally: revenue-per-employee rises, revenue-per-process falls, and whether the two cross positively decides the next five years.
What the market may be underestimating
Upside Agentic deployment inside large enterprises stalls on data plumbing, exception governance and accountability — precisely the labor Genpact already performs. It could become the paid integrator/operator of other vendors' agents, converting a shrinking labor pool into a higher-margin operations-management annuity.
Downside The deflation may land asymmetrically on the highest-margin, most standardized work (F&A, procurement, order-to-cash) first, leaving Genpact holding the low-margin, unautomatable residue — a mix shift that compresses margins even if headline revenue holds.
Outcome range spread 48 · unresolved
Growth Outlook
Analyzed 2026-08-19 16:08The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting from the raw tape: Genpact is compounding revenue at ~6.6% YoY (Q2'26 $1.34B vs Q2'25 $1.25B) with net margins pinned in a tight 10.6–11.4% band across eight quarters. That is not a business in decay — it is a business in equilibrium. FY25 revenue of $5.08B (+6.5% over FY24) with operating income of $750M (+6.9%) shows operating leverage is intact, not compressing. The Market Forces model's claim of "declining profitability masked by revenue growth" is flatly wrong on the numbers: op margin went from 11.5% (FY22) to 12.7% (FY23) to 14.7% (FY24) to 14.8% (FY25). That is 320bps of expansion, not compression. The Thesis Evaluation's "320bp margin compression" bear point appears to be fabricated or inverted. FCF of $735M against a $5.82B market cap is a ~12.6% FCF yield, and capex is a trivial $78M — this is a genuine cash machine, not working-capital harvesting (OCF $813M vs NI $553M implies real accrual quality, not one-time releases).
Where I diverge from the synthesis: the $58 fair value feels aggressive for a business growing 6.5% with structural AI overhang. A more defensible frame is 12–14x FCF on $735M = $8.8–10.3B EV, minus $690M net debt = $8.1–9.6B equity, or roughly $48–57/share. So directionally the synthesis is right — $34.65 is cheap — but the "+45%" precision is spurious. I also disagree with the Market Forces "value trap" verdict: value traps have deteriorating unit economics; Genpact has expanding operating margins, 21.7% ROE, 17.5% ROIC, and D/E of 0.6. Those aren't trap metrics. The Narrative layer's read (80% fundamentals, 20% sector-rotation discount) is the most honest framing in the stack.
The contrarian case worth taking seriously isn't the one the bear models actually made. It's this: services businesses tend to re-rate down, not up, when AI enters the frame — Accenture is off ~35% from highs on this exact fear, and it's larger and more diversified. Even if Genpact's earnings hold flat for three years, the multiple could compress from 11.8x to 8–9x, taking the stock to $26–28. The insider data is uninformative — nine identical 6,521-share awards on 2026-04-23 is a board grant, not conviction. There have been zero open-market buys in the visible window, which for a stock management supposedly thinks is 45% undervalued is telling. The decelerating quarterly revenue trend (Q1'26 8% YoY → Q2'26 6.6% YoY) is also a real yellow flag — if deceleration continues into H2'26, the "growth is free" thesis weakens.
Committing: I partially agree with the undervalued verdict but with lower conviction and a tighter fair value band than $53–58. At $34.65 with a 12.6% FCF yield, 6-7% top-line growth, expanding margins, and modest leverage, the risk/reward is favorable — you're being paid to wait through the AI-disruption fog. Fair value $46–52 is defensible; anything above $55 requires believing Genpact successfully repositions into higher-value digital work, which the numbers don't yet prove. The prior models over-index on either the DCF output ($58) or the AI-disruption narrative (value trap) — the truth is a boring 30-35% underpricing that will likely close via multiple expansion to 14-15x earnings over 18-24 months, or via buyback-driven EPS growth if it doesn't. The Thesis Evaluation's -12 score is anchored on a bear point that contradicts the actual margin data, so I discount it heavily.
GPT Reading
What jumps out is that Genpact is not behaving like a melting-ice-cube outsourcer in the reported numbers. Revenue has stepped up from $4.02B in 2021 to $5.08B in 2025, a solid 6%-7% CAGR, and the quarterly run-rate has moved from $1.21B in 2025-03 to $1.34B in 2026-06. That latest quarter is up about 7.2% year over year versus $1.25B, and net income rose from $132.7M to $145.7M. Margins are not spectacular, but they are stable: quarterly net margin has stayed in a tight 10.6%-11.4% band for eight reported quarters, while annual operating margin improved from 11.5% in 2022 to 14.8% in 2025. For a company supposedly trapped in structural deterioration, the actual P&L shows resilience and modest improvement. The 2023 net income figure of $631.3M being above operating income likely reflects some non-operating or tax benefit, so I would not annualize that, but even normalizing around 2024-2025, Genpact is earning roughly $515M-$550M with consistency.
The other number that matters is cash. Operating cash flow of $812.9M and free cash flow of $734.7M on $5.08B of revenue is excellent conversion for this kind of services business, especially with just $78.2M of capex. Against a $5.82B market cap, that is roughly a 12.6% FCF yield; against net debt of about $686M ($1.54B debt less $853.8M cash), enterprise value is around $6.5B, or roughly 8.5x EBITDA and 1.38x revenue. Those are cheap-to-reasonable multiples for a business growing mid-single digits with 17.5% ROIC and 21.7% ROE. A stock at 11.9x earnings, 1.3x sales, and sub-9x EV/EBITDA does not need a glamorous AI reinvention to work; it only needs earnings durability. On the reported data, that durability is there. My read is that the market is over-discounting the “legacy BPO” label and underpricing a company that still appears to be compounding revenue, defending margins, and converting profit to cash.
I also don’t buy the harshest version of the AI-disruption bear case from the numbers in hand. If GenAI were already crushing pricing or shrinking demand, I would expect revenue stalls, gross-margin erosion, or at least more visible instability in quarterly profitability. Instead gross margin reached 36.0% in 2025, up from roughly 35.5% in 2024 and 35.1% in 2023, and operating income rose from $630.9M in 2023 to $750.2M in 2025. That does not prove immunity, but it does argue adaptation rather than displacement so far. The stock’s valuation already embeds skepticism more appropriate for a no-growth asset. Yet the business is growing, and the balance sheet is manageable with debt/equity at 0.61 and a current ratio of 1.66. If the company merely holds earnings around current levels, a low-teens earnings multiple supports something better than the mid-$30s; on $550M of normalized net income, even 14x implies an equity value near $7.7B before considering ongoing buybacks/dividends, comfortably above today’s $5.82B.
The best argument against this view is that the market is not stupid to leave a 12%-plus FCF yielder at 11.9x earnings. The opponent would say this is exactly what a secularly threatened services business looks like before the downturn becomes obvious: stable-looking numbers, low capex, strong near-term cash, but poor terminal value. They would also point to the odd mismatch between revenue CAGR of 6.5% and earnings CAGR of negative 6.5%, which says growth has not translated into sustained bottom-line compounding over the full period. Net income in 2025 at $552.5M is below the anomalously high 2023 result, and quarterly revenue progression from $1.29B in 2025-09 to $1.32B in 2025-12 to $1.30B in 2026-03 is not exactly explosive. If wage pressure, client concentration, or AI-led pricing compression hit even modestly, a 10%-11% net margin could slip to 8%-9%, and the “cheap” P/E would prove to be on peak earnings. That is the bear case I take seriously.
What keeps me on the bullish side is that you do not need heroic assumptions for upside, only non-deterioration. I would change my mind if upcoming quarters show revenue growth fading below 3% while net margin breaks below 10% for more than a quarter or two, because that would indicate the disruption thesis is finally showing up in the income statement. I would also rethink if free cash flow drops materially below $600M without an obvious temporary working-capital cause, or if net debt starts rising despite stable earnings. Short of that, this looks like a steady compounder being priced like an ex-growth problem asset.
Grok Reading
The raw numbers describe a steady mid-single-digit compounder that the market has simply stopped paying for. Genpact grew revenue from $4.02B in 2021 to $5.08B in 2025, a clean 6.5% CAGR, and the last eight quarters show the same cadence: $1.21B → $1.25B → $1.21B → $1.25B → $1.29B → $1.32B → $1.30B → $1.34B, with net margins locked in a 10.6–11.4% band. Operating income climbed from $509M to $750M over the same span; operating margin expanded from roughly 12.7% to 14.8%, the opposite of the compression story some models are selling. Free cash flow of $735M against a $5.82B market cap is a 12.6% FCF yield, backed by operating cash flow of $813M and only $78M of capex—this is not working-capital theater. ROE at 22% and ROIC at 17.5% on a 0.6× debt-to-equity balance sheet with $854M cash against $1.54B debt complete a picture of a mature earner that is still earning its cost of capital comfortably. At 11.9× earnings, 8.5× EV/EBITDA and 1.3× sales, the stock sits well below Cognizant’s roughly 17× and far below higher-growth digital peers; the valuation synthesis fair-value band near $53–58 is directionally consistent with capitalizing this cash stream at any non-distressed multiple.
The contradiction worth catching is between the “value-trap / AI obsolescence” overlay and the income statement itself. Earnings CAGR prints negative only because 2023 net income spiked to $631M; strip that year and the trajectory from 2021–22 levels ($350–370M) to 2024–25 ($514–553M) is solidly positive, and trailing twelve-month net income is still running above $580M. Quarterly revenue is labeled “decelerating,” yet year-over-year growth remains +6.6% with earnings +7.6%. Insider activity is noise—routine awards and a tax withholding—not distribution. The balance sheet and cash conversion give no evidence of a business in structural freefall; they show a labor-arbitrage franchise that has so far defended price and mix while layering digital work.
The strongest opposing case is straightforward: generative AI could hollow out the very process work that still dominates Genpact’s book faster than the company can reprice or reskill, turning today’s 12% FCF yield into a melting ice cube. Skeptics will correctly note that the stock has already been left behind by EXLS-type pure digital names, that India wage inflation remains a perpetual margin headwind, and that a sub-sector multiple of ~12× may be the equilibrium if growth permanently settles at 4–5% with zero re-rating catalyst. A private-equity takeout is a hope, not a plan, and the narrative layer is correctly described as low-intensity indifference rather than hidden accumulation. Those points justify a discount to growth IT services; they do not, on the evidence in hand, justify a multiple that prices in outright decline when revenue, operating profit and free cash flow are all still rising.
I would reverse to neutral or bearish if two consecutive quarters show revenue growth under 3% accompanied by operating margin back below 13%, or if management discloses material AI-driven contract losses or pricing resets that break the 10%+ net margin floor. A credible strategic bid above $45 or a sustained acceleration of digital/high-value work that pushes organic growth back above 8% with margin expansion would push me from undervalued to aggressively bullish.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has compounded from $4.02B (2021) to $5.08B (2025), a ~6% CAGR that accelerated in the last two years (+6.5% then +6.4%). Operating margin expanded from 12.7% to 14.8% while gross margin held at ~35-36%, indicating real operating leverage rather than mix-driven noise. FCF of $734.7M in 2025 is the highest in the five-year window and comfortably exceeds net income of $552.5M (OCF/NI 1.32x, accruals -2.4% of assets), so reported earnings are backed by cash. Beneish M of -2.72 shows no manipulation flags; Altman Z at 2.9 sits in the grey zone but is typical for asset-light services. Capital allocation is shareholder-friendly: diluted share count fell from 193.0M to 176.6M (-2.2% CAGR) with buybacks running 245% of SBC and SBC only 1.8% of revenue - genuine per-share value concentration. Liquidity is adequate: $1.20B cash, though net debt of $338.5M means the balance sheet is a mild constraint, not a fortress. Insider tape is neutral - the recent activity is routine director awards and tax-withholding F transactions, with essentially no open-market buying or selling of note (one small $114K sale over 12 months). Nothing in the raw data contradicts the module verdicts; the trajectory is one of quiet, consistent improvement.
Verify before trusting this (5)
- Cause of 2023 net income spike ($631M) vs surrounding years - tax benefit, gain, or genuine operating step-up?
- Customer concentration and contract duration disclosures in the 10-K
- Debt maturity schedule and interest coverage detail
- Segment/service-line mix (BPO vs digital/analytics) and organic vs acquired growth split
- AI/automation exposure - is it a tailwind or a structural threat to labor-arbitrage revenue?
The composite FV of $58.45 and signal-adjusted $53.38 imply 45% upside, but I trust the more conservative anchors here. The EPV floor of $44.60 and anchored P/E of $49.40 are the credible bookends for a mature BPO compounder; the DCF at $69.90 leans on terminal assumptions the market rightly won't underwrite while AI disruption risk is unresolved. Splitting the difference lands deserved value around $47-50 - a mid-teens P/E on clean, high-quality earnings for a business growing mid-single-digits with expanding margins and real buybacks. Against $36.45, that is a 20-30% gap. Not a fat-pitch dislocation, but a real discount driven by narrative (AI-will-eat-services) rather than deteriorating fundamentals. Earnings quality is high (score 2), so no haircut is warranted - cash conversion supports the reported numbers. The business quality is Strong but not fortress, which caps the multiple I'd pay. What's priced in at $36.45: roughly flat-to-declining earnings power, terminal-value skepticism, and a services-industry de-rating. What's NOT priced: the possibility Genpact actually monetizes AI as a revenue lever rather than being disintermediated. That optionality is free at this price, which is why I lean cheap rather than fair.
Verify before trusting this (4)
- Organic revenue growth trajectory ex-FX in next 2 quarters - is the base business actually decelerating or holding?
- Management commentary on AI as revenue driver vs. margin threat - concrete customer wins on GenAI offerings
- Buyback pace and capital allocation - is the share count reduction accelerating at these prices?
- Any client concentration disclosures or large contract renewals at risk
Sentiment pressure on G has quietly flipped positive over the last month. The tape is mildly risk-on and Genpact's low 0.58 beta means macro pushes barely move the needle - stock-specific narrative is doing the work. That narrative, historically a headwind (legacy BPO, AI-disintermediation fear), is being reframed: management's 'Agentic Operations' positioning plus a 13% one-month rally and press coverage attributing it to AI-focused solutions, buybacks and dividends suggest the market is starting to place G on the right side of the AI-services trade instead of the wrong side. That is a meaningful narrative shift for a name whose durability score was 'moderate' and cult coefficient 'low.' The offsets keep this from being a strong tailwind. Narrative intensity is still 'minimal' - there is no cult bid here, no momentum crowd, and the 5% sell-the-news reaction to a strong Q2 beat/raise on Aug 7 shows the marginal buyer is still skeptical and quick to fade good news. Analyst tone is not visibly inflecting, and IT-services as a cohort remains out of favor versus sexier AI infrastructure names. Net: a real but modest tailwind - the story is turning, the tape is friendly, but conviction from the Street is not there yet.
Verify before trusting this (4)
- Whether analyst target revisions start catching up to the price move (would confirm the narrative shift)
- Follow-through above the $35-40 range that has capped the name - a break signals the reframing is sticking
- Any large IT-services peer (Accenture, Infosys, Cognizant) commentary on AI cannibalization - a negative print there would drag G regardless of its own story
- Sector rotation signals - if AI capital rotates from infrastructure toward services adopters, G is a direct beneficiary
Genpact's job — run someone else's back office better and cheaper than they can — survives cheap intelligence completely; its delivery model does not. Labor arbitrage was the scarce asset, and AI makes the arbitraged input abundant, so the price of a processed invoice, claim, or ticket falls toward the cost of inference. Genpact's defense is that it holds the messy last mile: exception handling, regulatory accountability, integration into a client's specific ERP mess, and a client base that genuinely does not want to own compliance operations. That shield is real but thinner than PAYC's, because Genpact is not a system of record — SAP, Oracle, Workday and ServiceNow can embed agents directly in the system where the transaction lives and route around the BPO layer, and AI-native service startups can bid per-outcome with no labor base to defend. Structurally: revenue-per-employee rises, revenue-per-process falls, and whether the two cross positively decides the next five years.
Verify before trusting this (8)
- Per-transaction pricing at rebid
- Client-mandated AI savings clauses
- Gross margin direction vs 36%
- Disclosed non-FTE pricing mix
- Total contract value versus headcount
- Organic growth versus industry 10.5%
- Revenue per employee trajectory
- Headcount vs revenue divergence
The enterprise services world is in a mid-cycle digestion phase: neutral macro, 10y at 4.72 with a positively sloped 0.53 curve, and IT services demand deteriorating at the margin as clients ration discretionary transformation budgets while protecting run-the-business operations. That mix is favorable for Genpact's revenue shape — its core is run-the-business, contracted operations, not project work — but it caps upside because the high-growth consulting layer is exactly what gets deferred. The deeper world change is that the pricing unit of outsourced process work is migrating from labor hours to outcomes and software; whoever owns the process data and the client's workflow can reprice into that, and whoever only owns arbitraged labor cannot. Genpact sits ambiguously between those poles, which is why the near-term picture is far clearer than the 3-year one.
When we made this prediction on Aug 19, 2026, G was $36.41. We expect it to be $44.10 by Feb 2027, and we consider it great value under $34.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 19, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.